Caribou Biosciences (CRBU) Operating Expenses (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Operating Expenses data on file, last reported at $28.7 million in Q1 2026.

• On a quarterly basis, Operating Expenses fell 36.65% year-over-year to $28.7 million in Q1 2026; TTM through Mar 2026 was $142.9 million, a 17.6% decrease from a year earlier, with the FY2025 full-year figure at $159.5 million, down 9.69% from the prior year.
• Operating Expenses for Q1 2026 stood at $28.7 million, down from $32.4 million in the prior quarter.
• Over the last five years, Operating Expenses for CRBU reached as high as $50.2 million in Q2 2025 and fell as low as $23.5 million in Q1 2022.
• Historically, Operating Expenses has averaged $37.4 million across 5 years, with a median of $36.6 million in 2023.
• Across the five-year window, Operating Expenses surged 87.06% in 2022 and plunged 36.65% in 2026, its largest moves.
• Year by year, Operating Expenses stood at $34.3 million in 2022, then climbed by 19.64% to $41.0 million in 2023, then dropped by 0.12% to $41.0 million in 2024, then fell by 20.9% to $32.4 million in 2025, then decreased by 11.47% to $28.7 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $28.7 million in Q1 2026, $32.4 million in Q4 2025, and $31.6 million in Q3 2025.